U.S. markets open in 2 hours 44 minutes
  • S&P Futures

    4,620.00
    +53.75 (+1.18%)
     
  • Dow Futures

    34,747.00
    +290.00 (+0.84%)
     
  • Nasdaq Futures

    16,376.00
    +225.50 (+1.40%)
     
  • Russell 2000 Futures

    2,243.10
    +45.80 (+2.08%)
     
  • Crude Oil

    69.11
    +2.93 (+4.43%)
     
  • Gold

    1,787.10
    +10.60 (+0.60%)
     
  • Silver

    22.91
    +0.09 (+0.42%)
     
  • EUR/USD

    1.1331
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    1.4430
    0.0000 (0.00%)
     
  • Vix

    23.84
    +0.88 (+3.83%)
     
  • GBP/USD

    1.3322
    +0.0021 (+0.16%)
     
  • USD/JPY

    113.3390
    +0.1590 (+0.14%)
     
  • BTC-USD

    57,053.96
    -560.73 (-0.97%)
     
  • CMC Crypto 200

    1,466.04
    +23.27 (+1.61%)
     
  • FTSE 100

    7,149.37
    +89.92 (+1.27%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

CLASS ACTION UPDATE for BLUE, KDMN and EBON: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / April 13, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

BLUE Shareholders Click Here: https://www.zlk.com/pslra-1/bluebird-bio-inc-loss-form?prid=14635&wire=1
KDMN Shareholders Click Here: https://www.zlk.com/pslra-1/kadmon-holdings-inc-loss-submission-form?prid=14635&wire=1
EBON Shareholders Click Here: https://www.zlk.com/pslra-1/ebang-international-holdings-loss-submission-form?prid=14635&wire=1

* ADDITIONAL INFORMATION BELOW *

bluebird bio, Inc. (NASDAQ:BLUE)

BLUE Lawsuit on behalf of: investors who purchased May 11, 2020 - November 4, 2020
Lead Plaintiff Deadline : April 13, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/bluebird-bio-inc-loss-form?prid=14635&wire=1

According to the filed complaint, during the class period, bluebird bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Kadmon Holdings, Inc. (NASDAQ:KDMN)

KDMN Lawsuit on behalf of: investors who purchased October 1, 2020 - March 10, 2021
Lead Plaintiff Deadline : June 2, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/kadmon-holdings-inc-loss-submission-form?prid=14635&wire=1

According to the filed complaint, during the class period, Kadmon Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Belumosudil NDA was incomplete and/or deficient; (ii) the additional new data that the Company submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the NDA submission; (iii) accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe; (iv) accordingly, the FDA was likely to extend the PDUFA target action date to review the Belumosudil NDA; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Ebang International Holdings Inc. (NASDAQ:EBON)

EBON Lawsuit on behalf of: investors who purchased June 26, 2020 - April 5, 2021
Lead Plaintiff Deadline : June 7, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ebang-international-holdings-loss-submission-form?prid=14635&wire=1

According to the filed complaint, during the class period, Ebang International Holdings Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the proceeds from Ebang's public offerings had been directed to an low yield, long term bonds to an underwriter and to related parties rather than used to develop the Company's operations; (2) Ebang's sales were declining and the Company had inflated reported sales, including through the sale of defective units; (3) Ebang's attempts to go public in Hong Kong had failed due to allegations of embezzling investor funds and inflated sales figures; (4) Ebang's purported crytocurrency exchange was merely the purchase of an out-of-the-box crypto exchange; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/640175/CLASS-ACTION-UPDATE-for-BLUE-KDMN-and-EBON-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders